Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on September 8, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn243
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
81/3/465    most recent
cvn243v2
cvn243v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dorn, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorn, G. W., II
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Apoptotic and Non-apoptotic Programmed Cardiomyocyte Death in Ventricular Remodeling

Gerald W. Dorn, II, MD

Center for Pharmacogenomics and Cardiovascular Division, Department of Internal Medicine, Washington University

Correspondence to: Gerald W. Dorn II, M.D. Washington University Center for Pharmacogenomics 660 S. Euclid Ave., Campus Box 8086 St. Louis, MO 63110. Phone: 314-362-8901. FAX: 314-362-0186. Email: gdorn{at}dom.wustl.ed

A defining cellular event in the transition from compensated hypertrophy to dilated cardiomyopathy is cardiomyocyte drop-out due to apoptosis, programmed necrosis, and autophagy. The importance of apoptosis in heart failure has been recognized for over a decade, while other forms of programmed cell death have more recently been appreciated, and their pathophysiological roles continue to be defined in experimental and clinical heart failure. The major focus of this review is on apoptosis in heart failure, with a discussion of molecular cross-talk between apoptosis, autophagy, and programmed necrosis.

Time for primary review: 17 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. Clerk and P. H. Sugden
Dying by the way you live: AIF vs. caspases in apoptosis of hypertrophied cardiomyocytes
Cardiovasc Res, November 14, 2009; (2009) cvp349v2.
[Full Text] [PDF]

Home page
 Circ Heart FailHome page
K. Seki, S. Sanada, A. Y. Kudinova, M. L. Steinhauser, V. Handa, J. Gannon;, and R. T. Lee
Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling
Circ Heart Fail, November 1, 2009; 2(6): 684 - 691.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Kassiotis, K. Ballal, K. Wellnitz, D. Vela, M. Gong, R. Salazar, O. H. Frazier, and H. Taegtmeyer
Markers of Autophagy Are Downregulated in Failing Human Heart After Mechanical Unloading
Circulation, September 15, 2009; 120(11_suppl_1): S191 - S197.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Diez and G. Ertl
A translational approach to myocardial remodelling
Cardiovasc Res, February 15, 2009; 81(3): 409 - 411.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.